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Abstract
Background: There is limited data on the genotype distribution of human papillomavirus (HPV) in the Taihu River
Basin, home to 1.29 million people on the coast of eastern China. This study evaluated the prevalence and
genotypes among different female age groups in this region.
Methods: Twenty-six HPV strains (low-risk HPV 6, 11, 40, 42, 44, 61, 73 and high-risk HPV 16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 82, and 83) were detected using Tellgenplex™ HPV technology in samples
obtained from three clinical hospitals located in different regions of the Taihu Lake Basin.
Results: The results showed that 1855 samples (20.97% of all samples) were found to be HPV-positive. Of these,
1375 samples (15.55% of all samples) were found to have a single HPV infection. Age-specific prevalence showed
two peaks, one that corresponded to the group of 21–30 year-old women and the other peak that corresponded
to the group of women over 51 years old. The three most prevalent genotypes were HPV52 (19.95%, 370/1855),
HPV16 (13.48%, 150/1855), and HPV58 (11.32%, 210/1855). Mixed strains HPV58 + HPV33 and HPV58 + HPV52 were
most commonly found in females infected with multiple HPV types.
Conclusions: This investigation reveals that HPV infection in the Taihu River Basin varied significantly among
different age groups. The most prevalent genotypes are included in the nonavalent vaccine, V503, however this
vaccine is not licensed for use in mainland China. The most frequently occurring genotypes should be considered
in the development of next-generation HPV vaccines for optimal protection of public health.
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Background
Cervical cancer (CC) is a major cause of morbidity and
mortality among women in China, and also represents
an important global public health problem. Persistent
infection by high-risk human papillomavirus (hrHPV) is
required for the development of pre-invasive and
invasive carcinogenesis [1, 2]. To date, more than 200
different viral types have been identified, and 40 of these
types can infect the mucosa of the anogenital tract
[3]. To some extent, improved detection of hrHPV
may reduce the risk for the development of CC and
associated deaths [4].
Early studies demonstrated that the distribution of
HPV genotypes in CC varies with geographic location
[2, 5, 6]. Hence, an accurate assessment of the
regional genotype distribution is very important for effect-
ive strategies to prevent CC. Several studies have assessed
the prevalence of HPV strains in mainland China, such as
studies focused on Yunnan and Shanghai [7, 8] and a
study that examined the HPV distribution in 37 cities in
China [9]. However, there is limited data on the genotype
distribution in the Taihu River Basin, which is a largely
agricultural and industrial coastal area in eastern
China. HPV genotyping detection is used to study
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HPV strain-specificity to facilitate the implementation,
monitoring, and evaluation of vaccination programs.
The American Society for Colposcopy and Cervical
Pathology (ASCCP) guideline indicated that cervical
screening should start at the age of 21, and screen-
ing using both the HPV test and the Pap test
should be performed every 5 years for women 30–
65 years in age [10]. The aim of this study was to
determine the distribution of HPV genotypes in the
Taihu River Basin to facilitate a better understand-




The purpose of this investigation was to obtain data on
the prevalence of HPV genotypes, including age-specific
prevalence differences and the distribution of multiple
HPV genotypes. This investigation analyzed samples
obtained from 3 clinical hospitals located in different
regions of the Taihu River Basin. From November 2013
and June 2015, a total of 9012 women aged 21–70 years
old (14,280 subjects were invited, but 5268 patients did
not participate in the screening for various reasons)
attended a gynecological outpatient clinic and expressed
interest in cervical cancer screening. Participants met
the following selection criteria: a) had not had sexual
intercourse, had not used vaginal medications, and had
not washed in the previous 48 h; b) not currently
pregnant; c) with no history of total uterus or cervix
resection; d) a permanent resident of the region; and
e) agreed to undergo the HPV test and participate in
this study.
Specimen collection
The cervico-vaginal cells at the transformation zone of
the uterine cervix were collected from all participants by
a gynecologist using a standard cytobrush according to
the standard sampling procedure at the recruitment
sites. Cells were resuspended in 3 ml sample transport
medium (STM) for the Tellgenplex™ HPV DNA Test
(Tellgen Life Science, Shanghai, China) and stored at 4 °C.
According to the kit instructions, samples can be stored in
STM for 1 month at 2–8 °C and 6 months at −20 °C. We
stored all samples at 4 °C for 1 week prior to testing to
obtain the most accurate results.
Ethics statement
This investigation was approved by the Ethical Commit-
tee of Wujiang First Hospital affiliated with Nantong
University (permit number: 201405). All the specimens
and their corresponding information were obtained with
written informed consent from the participants involved
in the project.
HPV Genotyping
The Tellgenplex™ HPV DNATest uses one multiplex PCR
test combined with Luminex technology to identify the 26
most common HPV types (−6, −11, −16, −18, −26, −31,
−33, −35, −39, −40, −42, −44, −45, −51, −52, −53, −55,
−56, −58, −59, −61, −66, −68, −73, −82, and −83). The
procedure includes DNA extraction, PCR amplification,
and bead-coated hybridization and was performed ac-
cording to the manufacturer’s guidelines [9, 11]. Each
assay required 10–20 pg/ml HPV DNA as template.
Females who were negative for β-globin were ex-
cluded from analyses.
Statistical analysis
All statistical analyses were performed using SPSS
version 19.0 (IBM, Armonk, NY, USA). All genotypes
from single and multiple infections were computed indi-
vidually. A multiple-type infection was defined as one
that was positive for at least 2 types. These data were
also stratified by age (21–30 years, 31–40 years, 41–
50 years, 51–60 years, and 61–65 years).
Results
Distribution characteristics of HPV genotypes
Among the 9012 individuals included in this study, 29
specimens were found to be negative for β-globin, and
138 cases could not be grouped because the analysis was
restricted to women 21–65 old. Therefore, 8845 subjects
(the median age was 42 and the quartile range was
32–47 years) were included in the analysis. As shown
in Fig. 1, the overall prevalence of HPV was 20.97%
(1855/8845), and 15.55% (1375/8845) of positive sam-
ples were found to have a single HPV infection, more
than the number of subjects with a multiple infection.
Among the study participants, 1430 had hrHPV infec-
tions, accounting for approximately 77% of the posi-
tive samples. The top 4 high-risk genotypes, 52, 16,
58, and 18, were detected in 19.95%, 13.48%, 11.32%,
and 9.43% of positive specimens, respectively. HPV52
was the most prevalent type in subjects with a single
HPV infection (260/1855 = 14.02%). Among the 480 indi-
viduals infected with multiple HPV types, 380 had dual
infections (380/480 = 79.17%), and 100 subjects were in-
fected by at least three HPV types (100/480 = 20.83%).
The four most prevalent high-risk HPV types for subjects
infected with multiple strains were HPV16, 52, 58, and 18,
with frequencies of 6.20%, 5.93%, 4.58%, and 4.58% of
positive samples, respectively.
Prevalence of HPV infection in different age groups
Among the age groups, the HPV infection prevalence
ranged from 16.3% for women aged 31–40 years to 25%
for those 51–60 yeas old (Fig. 2a, b). The frequency of
hrHPV types also differed among these age groups.
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Similar to the overall prevalence of HPV, the highest over-
all prevalence of hrHPV was found in women 51–60 years
old (16.67%, 75/450), and the lowest hrHPV prevalence
was found in women 31–40 years old (12.17%, 280/2300;
Fig. 2b). The prevalence for single and dual HPV infec-
tions exhibited two peaks, one for the group 21–30 years
old and the other for the group 51–60 years old (Fig. 2a).
Discussion
HPV infection is the most common sexually transmitted
infection. The majority of HPV infections are temporary,
especially among young women, but CC usually develops
after 10 years of persistent hrHPV infection [12]. Regular
gynecological screening and treatment of precancerous
lesions are less effective strategies for the prevention
Fig. 1 The top 10 HPV positive genotypes and their contribution
Fig. 2 a Relative contribution of single and multiple HPV infections by age at diagnosis. b Relative contribution of high- and low-risk HPV
infection by age at diagnosis
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of adenocarcinoma [13]. Fortunately, adenocarcinoma
should be controllable by HPV vaccines [14]. Two differ-
ent prophylactic HPV vaccines have been licensed and are
now available in most countries except Mainland China.
Obtaining a current dataset for a particular region will
enable the development of optimal and effective screening
and vaccination programs.
In this study, a rate of 20.97% HPV infection was
observed in patients ranging from 21 to 65 years old.
Most patients had a single infection. Of these HPV-
positive patients, 77.09% were hrHPV infections, and
there were two peaks in this analysis corresponding to
women 21–30 years old and 51–60 years old. HPV is a
sexually transmitted disease, and the higher rate of infec-
tion in younger, single women may be because these
women may have more frequent sexual intercourse,
particularly with more than one partner. Older women
also show a higher rate of infection due to effects of
physiological and immunological disorders associated
with hormone fluctuations during the menopausal tran-
sition. These two peaks were also observed in the fre-
quency analysis of multiple infections. Additionally, the
frequency of dual and 3+ HPV infections was highest in
individuals over 50 years old. These trends are consistent
with the results of other researches that reported a
second peak for the prevalence of multiple infections in
females who are ≥50 or 60 years of age [8, 9, 12].
Of the three most dominant HPV genotypes, HPV 52,
HPV 16, and HPV 58, 70.3%, 54%, and 59.5%, respect-
ively, were single-infections and the remaining cases of
these genotypes were present together with other HPVs.
Wang et al. [15] reported that infections with multiple
genotypes had higher risk of the development and pro-
gression of CC, but this does not necessarily mean that
the cancerous stage requires multiple infections. Because
cervical precursor lesions need years to develop into CC,
multiple types may facilitate growth during the precan-
cerous Cervical Intraepithelial Neoplasia (CIN) stages,
but the oncogenic capability of the latter stages may not
be controlled by multiple genotypes. In this present
study, the top most frequent combinations of genotypes
were HPV58 + HPV33 (32 cases) and HPV58 + HPV52
(25 cases) (Additional file 1: Table S1.). Both HPV52 and
HPV58 are more prevalent in Eastern Asia, and the link-
ing of HPV58 to cervical cancer was 1.8 higher than for
HPV52 [16]. Further comparative analysis showed that
HPV16, 52, and 58 are the three top hrHPV types in the
Chinese reports, but the relative prevalence rates varied
widely and other genotype distributions also differed re-
gionally in Mainland [7, 17–19]. Therefore, infection
with HPV58 or 52 in this region should be given the
same attention as HPV16 and 18 infections. Fortunately,
the V503 nonavalent vaccine appears to be safe and
effective in the prevention of persistent infection and
precancerous lesions associated with hrHPV types −16,
−18, −31, −33, −45, −52, and −58, as well as genital
warts that are related to lrHPV 6 and 11 infection [20].
This would cover 70.18% (965/1375) of single infections
and 51.46% (247/480) of multiple infections in this area.
However, this vaccine is not licensed in mainland China.
This analysis of HPV genotype distribution in the
Taihu River Basin in China has potential limitations.
First, this study determined the distribution of the
prevalence of HPV genotypes in women aged 21–65 years
who attended a cervical screening, however, the absence
of cytological data of cervical pre-cancer or cancer re-
mains a major concern. Second, there was no sampling of
tissue specimens in this study. Comparison of HPV
detection rates between cervical scraping and biopsy
methods may help to clarify the pathological mechanism
of HPV infection and the evolution of CC. Overall, this
study provides a description of the genotype-specific
prevalence in women from the Taihu River Basin on the
coast of eastern China.
Conclusions
Lifestyle and health are dramatically affected by economic
conditions, cultural habits, and changing population dy-
namics. Therefore, it is urgent to pay attention to changes
in the prevalence of HPV infection, particularly at a re-
gional level. In the Taihu River Basin, the coast of eastern
China, we found that the three top genotypes were HPV
52 (19.95%), HPV 16 (13.48%), and HPV 58 (11.32%).
Mixed strains HPV58 + HPV33 and HPV58 + HPV52
were most frequently found in women with multiple
infections. Considering the specific genotypes present in
this geographic location, a cost-effective vaccine, such as
the nonavalent vaccine V503, may provide optimal pre-
vention of cervical cancer in this area.
Additional file
Additional file 1: Table S1. Characteristics of HPV co-infection. (DOCX 14 kb)
Abbreviations
CC: Cervical cancer; CIN: Cervical intraepithelial neoplasia; HPV: Human
papillomavirus; hr-: High-risk; lr-: Low-risk
Acknowledgements
Special thanks to the staff for their help in carrying out this study. We also
thank the staff of the sciworks language service for medical writing services.
Research support: Social development plan, soft science research project of
Wujiang area in Suzhou, Jiangsu Province, China (grant number WS201302).
Funding
This present study was financially supported by the Social Development Plan
and Soft Science Research Project of Wujiang Area in Suzhou, Jiangsu
Province, China (grant number WS201302).
Availability of data and materials
Our data will not be shared to protect the participants’ anonymity.
Lu et al. BMC Infectious Diseases  (2017) 17:226 Page 4 of 5
Authors’ contributions
QL, CFM, THZ, XC coordinated and performed all sample analyses. JFL and
GRS drafted and revised the manuscript. All authors read and approved the
final manuscript.
Competing interests




Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 26 October 2016 Accepted: 17 March 2017
References
1. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
et al. Human papillomavirus genotype attribution in invasive cervical cancer:
a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):
1048–56.
2. Al Moustafa AE, Ghabreau L, Akil N, Rastam S, Alachkar A, Yasmeen A.
High-risk HPVs and human carcinomas in the Syrian population. Front
Oncol. 2014;4(1):68.
3. Padalko E, Ali-Risasi C, Mesmaekers S, et al. Comparative analysis of cervical
cytology and human papillomavirus genotyping by three different methods
in a routine diagnostic setting. Eur J Cancer Prev. 2015;24(5):447–58.
4. Villiers EMD. Cross-roads in the classification of papillomaviruses. Virology.
2013;445(1–2):2–10.
5. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human
papillomavirus type distribution in 30,848 invasive cervical cancers
worldwide: Variation by geographical region, histological type and year of
publication. Int J Cancer. 2011;128(4):927–35.
6. Roteli-Martins CM, de Carvalho NS, Naud P, Teixeira J, Borba P, Derchain S,
et al. Prevalence of human papillomavirus infection and associated risk
factors in young women in Brazil, Canada, and the United States: a
multicenter cross-sectional study. Int J Gynecol Pathol. 2011;30(2):173–84.
7. Li Z, Liu F, Cheng S, et al. Prevalence of HPV infection among
28,457 Chinese women in Yunnan Province, southwest China. Sci.
Rep. 2016;6:21039.
8. Singh S, Zhou Q, Yu Y, Xu X, Huang X, Zhao J, et al. Distribution of HPV
genotypes in Shanghai women. Int J Clin Exp Pathol. 2015;8(9):11901.
9. Wang R, Guo XL, Wisman GBA, et al. Nationwide prevalence of human
papillomavirus infection and viral genotype distribution in 37 cities in China.
BMC Infect Dis. 2015;15(1):257.
10. Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S,
Saslow D, et al. Cancer screening in the United States, 2015: a review of
current American Cancer Society guidelines and current issues in cancer
screening. CA Cancer J Clin. 2015;65(1):30–54.
11. Wei W, Shi Q, Guo F, Zhang BY, Chen C, Zhang NS, et al. The distribution of
human papillomavirus in tissues from patients with head and neck
squamous cell carcinoma. Oncol Rep. 2012;28(5):1750–6.
12. Jing L, Zhong X, Zhong Z, et al. Prevalence of human papillomavirus
infection in Guangdong Province, China: a population-based survey of
78,355 women. Sex Transm Dis. 2014;41(12):732–8.
13. Chew GK, Cruickshank ME, Rooney PH, Miller ID, Parkin DE, Murray GI.
Human papillomavirus 16 infection in adenocarcinoma of the cervix.
Br J Cancer. 2005;93(11):1301–4.
14. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination
coverage among adolescents, 2007-2013, and postlicensure vaccine safety
monitoring, 2006-2014-United States. MMWR. 2014;63(29):620–4.
15. Wang L, Wu B, Li J, et al. Prevalence of human papillomavirus and its
genotype among 1336 invasive cervical cancer patients in Hunan province,
central south China. J Med Virol. 2014;87(3):516–21.
16. Chan P K, Ho W C, Chan M C, Wong M C, Yeung A C, Chor J S, et al. Meta-
Analysis on Prevalence and Attribution of Human Papillomavirus Types 52
and 58 in Cervical Neoplasia Worldwide 2014.
17. Bi Q, Zhang L, Zhao Z, Mu X, Zhang M, Wang P. Human papillomavirus
prevalence and genotypes distribution among female outpatients in
Qingdao, East China. J Med Virol. 2015;87(12):2114–21.
18. Hong H, He TF, Ni HX, Zhang S, Xu GZ. Prevalence and genotype
distribution of HPV infection among women in Ningbo, China. Int J Gynecol
Obstet. 2015;131(1):96–9.
19. Xue H, Lin X, Li T, Yan X, Guo K, Zhang Y. Prevalence and genotype
distribution of human papillomavirus infection in asymptomatic women in
Liaoning province, China. J Med Virol. 2015;87(7):1248–53.
20. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503
on the horizon. Expert Rev. Vaccines. 2014;13(11):1279.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lu et al. BMC Infectious Diseases  (2017) 17:226 Page 5 of 5
